Credit: Michael Topper and Michelle Vaz
Combination therapy attracts immune cells to fight tumors and blocks cancer gene MYC Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy drugs, used together, achieved robust anti-tumor responses in human cancer cell lines and mice.